Abstract
The risk of Henoch-Schönlein purpura (HSP) following vaccination with a group B meningococcal vaccine was assessed through active hospital safety monitoring. There was no increase in the relative incidence of HSP within 30 days after vaccination nor recurrence in HSP cases who received one or more further vaccine doses (re-challenge).
MeSH terms
-
Child
-
Child, Preschool
-
Drug Eruptions / epidemiology
-
Drug Eruptions / etiology*
-
Female
-
Humans
-
IgA Vasculitis / chemically induced*
-
IgA Vasculitis / epidemiology
-
Immunization Programs
-
Immunization Schedule
-
Incidence
-
Infant
-
Male
-
Meningococcal Vaccines / adverse effects*
-
New Zealand / epidemiology
-
Vaccination / adverse effects